Status:

COMPLETED

ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

Lead Sponsor:

Voyager Pharmaceutical Corporation

Conditions:

Alzheimer's Disease

Eligibility:

All Genders

60+ years

Phase:

PHASE3

Brief Summary

The study is designed to investigate the activity of the hormone drug leuprolide acetate in stabilizing cognitive function in mild-to-moderate AD patients.

Detailed Description

VP4896 is a gonadotropin releasing hormone (GnRH) agonist that binds to and inactivates GnRH receptors on the pituitary gland. This decreases the amount of luteinizing hormone released by the pituitar...

Eligibility Criteria

Inclusion

  • 60 years of age or older
  • Diagnosis of probable mild-to-moderate Alzheimer's Disease
  • On a stable dose of an acetylcholinesterase inhibitor (including, but not limited to: donepezil, galantamine, rivastigmine, and tacrine) for at least 120 days prior to baseline and will likely remain on the drug throughout the trial; all participants must be on acetylcholinesterase inhibitors
  • No other significant or interfering medical conditions

Exclusion

  • Significant neurological disease affecting the brain or psychiatric disease other than AD, such as current untreated major depression, schizophrenia, epilepsy, Parkinson's disease, Creutzfeldt-Jakob's disease, or clinical episode of stroke
  • Laboratory or clinical signs of untreated, clinically significant abnormal thyroid function, in the Investigator's opinion
  • Received other investigational drugs within 30 days or 5 half-lives prior to baseline, whichever is longer
  • Taking other medications, with the exception of estrogen, known to affect serum gonadotropin (Gn) concentrations, including but not limited to goserelin, danazol, or leuprolide
  • Other exclusion criteria exist--eligibility can be assessed by the trial site

Key Trial Info

Start Date :

September 1 2005

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

555 Patients enrolled

Trial Details

Trial ID

NCT00231946

Start Date

September 1 2005

Last Update

September 20 2007

Active Locations (59)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (59 locations)

1

Pivotal Research Centers

Peoria, Arizona, United States, 85381

2

NeuroSpecialists, PLLC

Tucson, Arizona, United States, 85741

3

Margolin Brain Institute

Fresno, California, United States, 93720

4

Bay Area Research Institute

Lafayette, California, United States, 94549